Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 2/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19275138 | 1.00 | GNAO1 (0.57) | GNAO1GNAI3GNAI1KDM4EGAA | |
| SCHEMBL26749002 | 1.00 | GNAO1 (0.57) | GNAO1GNAI3GNAI1KDM4EGAA | |
| SCHEMBL10244464 | 0.98 | GNAO1 (0.53) | GNAO1GNAI3GNAI1KDM4EGAA | |
| SCHEMBL10057623 | 0.91 | GNAI3 (0.45) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL6662182 | 0.91 | HRH3 (0.46) | GNAO1GNAI3GNAI1 | |
| SCHEMBL6659624 | 0.89 | HRH3 (0.42) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21934600 | 0.84 | HRH3 (0.36) | GNAO1GNAI3GNAI1GAALMNA | |
| SCHEMBL6658878 | 0.84 | HRH3 (0.36) | GNAO1GNAI3GNAI1GAALMNA | |
| SCHEMBL11571907 | 0.84 | GNAI3 (0.74) | GNAO1GNAI3GNAI1KDM4EGAA | |
| SCHEMBL7991671 | 0.84 | GNAI3 (0.74) | GNAO1GNAI3GNAI1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | GNAO1 2416/4885GNAI3 1630/4885GNAI1 1034/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | GNAO1 3651/4885GNAI3 3676/4885GNAI1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.